Dynavax and GlaxoSmithKline are working together to develop novel inhibitors of endosomal TLRs for the treatment of multiple autoimmune and inflammatory diseases. TLRs are key receptors of the innate immune system.. Dynavax and GlaxoSmithKline Select clinical candidate in the endosomal TLR Inhibitor ProgramDynavax Technologies Corporation today announced the selection of a candidate for clinical development in its endosomal Toll-like receptor inhibitor cooperation with GlaxoSmithKline.
About TLR inhibitorsDynavax endosomal TLR inhibitors are a new class of oligonucleotides, called immunoregulatory sequences , which specifically inhibit the TLR – induced inflammatory response associated with autoimmune and inflammatory diseases. Preclinical data from animal model studies show Dynavax’s TLR inhibitors block the induction of IFN – alpha and also the symptoms in several animal models of autoimmune diseases, such as lupus, inflammatory skin disease and rheumatoid arthritis.Biomedical Technology Solutions Holdings, pleased to announce BMTS known to -store Demolize II to Sharps Programme dispose and placement of the first Demolize II in one Kroger pharmacy. Of this program has been developed to be a valuable, full-service solution establish crisp life cycle chemist injection client. With over 2,000 pharmacy stores in the U.S., placing first system a Kroger pharmacies is a major benchmark on BMTS.